Best Practices for Complying with 340B

The Public Health Service Act 340B Drug Pricing Program enables providers that serve vulnerable patient populations to access outpatient drugs at significantly lower costs, which helps improve overall patient care. But for pharmaceutical manufacturers, program management can be extremely challenging.

Changes to the 340B program have led to an increase in the number of covered entities and contract pharmacies, as well as more stringent financial and legal implications for price errors.

For pharmaceutical manufacturers that participate in the 340B program, effective management of pricing, rebates, and chargebacks is crucial to protecting revenue streams and ensuring compliance. In this white paper, you’ll learn how you can improve your chargeback process, generate an audit trail, and ensure correct 340B pricing.